PMID: 2091630Jul 1, 1990Paper

Effective bronchodilator treatment by a simple spacer device for wheezy premature infants

Archives of Disease in Childhood
B YukselI Maconochie

Abstract

Ten preterm infants with recurrent respiratory symptoms (median gestational age 30 weeks) were entered into a non-randomised placebo controlled trial of bronchodilator treatment at 12.5 months of age. The infants had coughed or wheezed, or both, on at least four days a week for the past month. The infants received either placebo or 500 micrograms terbutaline from an inhaler using a coffee cup as a spacer device. Each treatment was maintained for two weeks, first placebo then active drug. The symptom score was reduced by 65% during the active treatment period compared with the placebo period and this was associated with a 32% improvement in lung function, reflected in an increase in functional residual capacity. We conclude that inhaled bronchodilator treatment given with a simple spacer device is useful for preterm infants with recurrent respiratory symptoms in the first two years of life.

References

Jul 1, 1978·Archives of Disease in Childhood·W Lenney, A D Milner
Jan 21, 1989·BMJ : British Medical Journal·C O'CallaghanA Swarbrick
Jun 1, 1989·American Journal of Diseases of Children·G BentonJ Okikawa
Jan 1, 1989·Archives of Disease in Childhood·B AndréassonB Jonson
Dec 1, 1988·Early Human Development·E Bowman, V Y Yu
Jul 1, 1986·Archives of Disease in Childhood·E S ParkS Stewart-Brown

❮ Previous
Next ❯

Citations

Oct 1, 1991·European Journal of Pediatrics·B Yuksel, A Greenough
Sep 1, 1992·European Journal of Pediatrics·B Yuksel, A Greenough
Sep 14, 2001·Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology·C MarguetE Mallet
Feb 2, 1996·Journal of Aerosol Medicine : the Official Journal of the International Society for Aerosols in Medicine·R Kraemer
Feb 1, 1997·Acta Paediatrica Japonica; Overseas Edition·R CengizlierA Tuncer
Apr 1, 1992·Acta Paediatrica·P J Thompson, A Greenough
Oct 1, 1990·Archives of Disease in Childhood·A Greenough
Apr 1, 1993·Archives of Disease in Childhood·C O'Callaghan
Oct 12, 1996·BMJ : British Medical Journal·H Bisgaard
Jul 31, 2003·American Journal of Respiratory and Critical Care Medicine·Julian AllenUNKNOWN American Thoracic Society
Nov 1, 1991·The British Journal of Radiology·B YukselA Page
Oct 15, 2008·Seminars in Fetal & Neonatal Medicine·Tai-Fai Fok
May 17, 2006·Primary Care Respiratory Journal : Journal of the General Practice Airways Group·Thys van der MolenRaj B Singh
Sep 1, 1996·Respiratory Medicine·B Yüksel, A Greenough
Jun 1, 1994·Pediatric Pulmonology·K N DesagerP A Vermeire
Jan 1, 1991·Archives of Disease in Childhood·P J FlemingJ Holton
Jan 1, 1991·Archives of Disease in Childhood·N Cimolai, J E Carter
Mar 15, 2005·Current Opinion in Allergy and Clinical Immunology·Bianca Schaub, Erika von Mutius
Jun 28, 2019·Expert Review of Respiratory Medicine·Emma Williams, Anne Greenough
Feb 14, 2021·Pediatric Pulmonology·Eli RhoadsClement L Ren

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.